Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer

被引:140
作者
Akashi, Takuya [1 ,2 ]
Koizumi, Keiichi [2 ]
Tsuneyama, Koichi [3 ]
Saiki, Ikuo [2 ,4 ]
Takano, Yasuo [3 ]
Fuse, Hideki [1 ]
机构
[1] Toyama Univ, Dept Urol, Grad Sch Med & Pharmaceut Sci Res, Toyama 930, Japan
[2] Toyama Univ, Dept Biosci, Natl Inst Med, Div Pathogen Biochem, Toyama 930, Japan
[3] Toyama Univ, Dept Pathol, Grad Sch Med & Pharmaceut Sci Res, Toyama 930, Japan
[4] Toyama Univ, COE Program 21st Century, Toyama 930, Japan
关键词
D O I
10.1111/j.1349-7006.2007.00712.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The chemokine receptor CXCR4 has been reported to be aberrantly expressed in human cancers and has also been shown to participate in the development of cancer metastasis. The present study was carried out to assess immunohistochemically the pattern of CXCR4 expression in patients with metastatic prostate cancer. We analyzed whether there may be an association between CXCR4 expression and prognosis. Fifty-two patients who received hormonal therapy were enrolled. Specimens were obtained from transperineal needle biopsy before treatment, and were stained with antihuman CXCR4 antibody. We also evaluated the pathological grade, extent of bony metastasis, clinical response to hormonal therapy, and patient prognosis. CXCR4 was detected in 94.2% patients. Its expression showed no association with pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. Patients with a high expression of CXCR4 in tumors had poorer cancer-specific survival than those with low expression of CXCR4. CXCR4 expression is a useful prognostic factor for patients with metastatic prostate cancer treated with androgen-withdrawal therapy.
引用
收藏
页码:539 / 542
页数:4
相关论文
共 27 条
[1]
Lymphocyte trafficking and regional immunity [J].
Butcher, EC ;
Williams, M ;
Youngman, K ;
Rott, L ;
Briskin, M .
ADVANCES IN IMMUNOLOGY, VOL. 72, 1999, 72 :209-253
[2]
Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results [J].
Catalona, WJ ;
Smith, DS .
JOURNAL OF UROLOGY, 1998, 160 (06) :2428-2434
[3]
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis [J].
Darash-Yahana, M ;
Pikarsky, E ;
Abramovitch, R ;
Zeira, E ;
Pal, B ;
Karplus, R ;
Beider, K ;
Avniel, S ;
Kasem, S ;
Galun, E ;
Peled, A .
FASEB JOURNAL, 2004, 18 (09) :1240-+
[4]
Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100 [J].
De Clercq, E .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (09) :805-824
[5]
A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma [J].
Geminder, H ;
Sagi-Assif, O ;
Goldberg, L ;
Meshel, T ;
Rechavi, G ;
Witz, IP ;
Ben-Baruch, A .
JOURNAL OF IMMUNOLOGY, 2001, 167 (08) :4747-4757
[6]
HISTOLOGIC GRADING OF PROSTATE-CANCER - A PERSPECTIVE [J].
GLEASON, DF .
HUMAN PATHOLOGY, 1992, 23 (03) :273-279
[7]
Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process [J].
Hart, CA ;
Brown, M ;
Bagley, S ;
Sharrad, M ;
Clarke, NW .
BRITISH JOURNAL OF CANCER, 2005, 92 (03) :503-512
[8]
Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression [J].
Jiang, Yu-ping ;
Wu, Xiao-hua ;
Shi, Bin ;
Wu, Wen-xin ;
Yin, Gui-ran .
GYNECOLOGIC ONCOLOGY, 2006, 103 (01) :226-233
[9]
Kijima T, 2002, CANCER RES, V62, P6304
[10]
Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer [J].
Koishi, Kenji ;
Yoshikawa, Reigetsu ;
Tsujimura, Tohru ;
Hashimoto-Tamaoki, Tomoko ;
Kojima, Syoudou ;
Yanagi, Hidenori ;
Yamamura, Takehira ;
Fujiwara, Yoshinori .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (47) :7585-7590